Yan Leyfman: Researchers have shed light on a critical aspect of CAR-T therapy – long-term complications
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn about a paper by Elvira Umyarova et al. published in the Journal of Hematology and Oncology:
“Researchers from Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, led by Dr. Marcos De Lima, have shed light on a critical aspect of CAR-T therapy – long-term complications.
CAR-T has revolutionized treatment for relapsed/refractory (R/R) B-cell lymphomas and multiple myeloma (MM), but what about secondary primary malignancies (SPMs)?
Study Highlights:
- 246 patients (2016–2022) with a median follow-up of 38 months
- 8.5% (21 patients) developed SPMs
- 52% Non-melanoma skin cancer (38% squamous cell carcinoma)
- 33% Hematologic malignancies (MDS, AML)
- 14% Solid tumors (bladder, prostate, breast cancer)
Why it matters:
These findings suggest potential CAR-T-related risks, emphasizing the need for vigilant post-treatment surveillance and further research into underlying mechanisms.
What’s next?
Understanding predictive factors to guide long-term management in CAR-T survivors.”
“Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies”
Authors: Elvira Umyarova, Charles Pei, William Pellegrino, Qiuhong Zhao, Nidhi Sharma, Alma Habib, Audrey Sigmund, Timothy Voorhees, Marcos de Lima and Narendranath Epperla et al.
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023